L Katherine Moon
Family · Vancouver, WANPI 1518992494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 563 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 563 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Kowa Pharmaceuticals America, Inc.$1K
- Lilly USA, LLC$929
- Novo Nordisk$794
- Bausch Health US, LLC$416
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,34798%
- Education$1412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,289 |
| AbbVie | 103 | $1,236 |
| Kowa Pharmaceuticals America, Inc. | 62 | $1,177 |
| Lilly USA, LLC | 56 | $929 |
| Novo Nordisk | 61 | $794 |
| Bausch Health US, LLC | 38 | $416 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $325 |
| Amgen | 18 | $295 |
| Bayer | 20 | $252 |
| Boehringer Ingelheim | 18 | $235 |
| Pfizer | 14 | $223 |
| Astellas Pharma US Inc | 4 | $202 |
| Corcept Therapeutics | 7 | $150 |
| Johnson & Johnson | 15 | $145 |
| Amarin Pharma, Inc. | 15 | $143 |
| Biohaven Pharmaceuticals, Inc. | 20 | $136 |
| Exact Sciences | 7 | $99 |
| Azurity Pharmaceuticals, Inc. | 3 | $59 |
| GSK | 3 | $53 |
| Novartis | 3 | $47 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,489 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $75,296 |
| EliquisApixaban | 19 | $29,527 |
| FarxigaDapagliflozin Propanediol | 25 | $25,524 |
| JardianceEmpagliflozin | 18 | $21,591 |
| RybelsusSemaglutide | 13 | $17,538 |
| XareltoRivaroxaban | 12 | $14,445 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $12,119 |
| Levothyroxine Sodium | 192 | $3,533 |
| Bupropion XlBupropion Hcl | 50 | $2,322 |
| Potassium Chloride | 35 | $2,136 |
| Metformin Hcl ErMetformin Hcl | 87 | $2,086 |
| SynthroidLevothyroxine Sodium | 28 | $1,962 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 13 | $1,644 |
| Olmesartan Medoxomil | 89 | $1,640 |
| Pravastatin Sodium | 67 | $1,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $794 | $92,83464 claims |
| Boehringer IngelheimJardiance, Glyxambi | $235 | $33,71029 claims |
| PfizerEliquis | $223 | $29,52719 claims |
| AstraZenecaFarxiga | $1,289 | $25,52425 claims |
| Johnson & JohnsonXarelto | $145 | $14,44512 claims |
| AbbVieSynthroid | $1,236 | $1,96228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Vancouver
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
- Brittanee WorthySpokane Valley$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.